Pharmabiz10h
EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis
EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis: North Chicago, Illinois Monday, March 3, 2025, 15:00 Hrs [IST] AbbVie annou ...
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib ...
GlobalData on MSN3d
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...
Nasdaq3d
AbbVie's Upadacitinib Gets Positive CHMP Opinion For Treatment Of Adults With Giant Cell Arteritis
(RTTNews) - AbbVie (ABBV) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib ...
AbbVie announces CHMP opinion recommending approval of upadacitinib
AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion recommending the ...
Morningstar3d
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
The final European Commission decision is expected in the first half of 2025. If approved, upadacitinib would be the first and only oral advanced therapy for adults living with GCA. "Giant cell ...
pharmaphorum3d
AbbVie closes on Rinvoq approval in inflamed artery disease
JAK inhibitor Rinvoq (upadacitinib) has been backed by the CHMP as a 15mg, once-daily treatment for adults with GCA, an ...
AbbVie gets EU nod for its giant cell arteritis treatment
AbbVie (NYSE:ABBV) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), ...
Le Lézard3d
Fapon Biopharma Announces FDA Approval of IND for FP008, a First-in-Class Immunotherapy for Solid Tumors
Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the Investigational ...
Le Lézard3d
CNO Financial Group Honors Associate Paul Richard as Volunteer of the Year, Donates to 12 Nonprofits through Annual Invested in Giving Back® Program
CNO Financial Group, Inc. today recognized associate Paul Richard as its Volunteer of the Year and announced CNO's 2025 Invested in Giving Back® program ...
Too Old to Operate4d
Small Molecule Drugs in Pityriasis Rubra Pilaris Treatment
The following is a summary of “Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review,” published in the February 2025 issue of Frontiers in ...
pharmaphorum4d
AbbVie breaks new ground for IL-23 drug Skyrizi in IBD
both S1P inhibitors – and AbbVie’s JAK inhibitor Rinvoq (upadacitinib). Rinvoq is the other drug that AbbVie has developed to defend its immunology franchise, and is also growing well ...